Your browser doesn't support javascript.
loading
DNA methylome combined with chromosome cluster-oriented analysis provides an early signature for cutaneous melanoma aggressiveness.
Carrier, Arnaud; Desjobert, Cécile; Ponger, Loic; Lamant, Laurence; Bustos, Matias; Torres-Ferreira, Jorge; Henrique, Rui; Jeronimo, Carmen; Lanfrancone, Luisa; Delmas, Audrey; Favre, Gilles; Daunay, Antoine; Busato, Florence; Hoon, Dave S B; Tost, Jorg; Etievant, Chantal; Riond, Joëlle; Arimondo, Paola B.
Afiliación
  • Carrier A; Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
  • Desjobert C; Cancer Epigenetics Group, Josep Carreras Leukemia Research Institute (IJC), Barcelona, Spain.
  • Ponger L; Unité de Service et de Recherche USR 3388, CNRS-Pierre Fabre, Epigenetic Targeting of Cancer (ETaC), Toulouse, France.
  • Lamant L; CNRS UMR 7196, INSERM U1154, Sorbone university- National museum of natural history (NMNH), Paris, France.
  • Bustos M; Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Torres-Ferreira J; Department of Translational Molecular Medicine, Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, United States.
  • Henrique R; Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/P.CCC Porto Comprehensive Cancer Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Jeronimo C; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/P.CCC Porto Comprehensive Cancer Center, Porto, Portugal.
  • Lanfrancone L; Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/P.CCC Porto Comprehensive Cancer Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Delmas A; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/P.CCC Porto Comprehensive Cancer Center, Porto, Portugal.
  • Favre G; Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
  • Daunay A; Cancer Biology and Epigenetics Group, Research Center (CI-IPOP)/P.CCC Porto Comprehensive Cancer Center, Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal.
  • Busato F; Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto)/P.CCC Porto Comprehensive Cancer Center, Porto, Portugal.
  • Hoon DSB; Department of Pathology and Molecular Immunology, Biomedical Sciences Institute (ICBAS), University of Porto, Porto, Portugal.
  • Tost J; Department of Experimental Oncology, Instituto Europeo di Oncologia, Milan, Italy.
  • Etievant C; Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Riond J; Cancer Research Center of Toulouse, UMR 1037, INSERM, Université Toulouse III Paul Sabatier, Toulouse, France.
  • Arimondo PB; Laboratory for Functional Genomics, Fondation Jean Dausset-CEPH, Paris, France.
Elife ; 112022 09 20.
Article en En | MEDLINE | ID: mdl-36125262
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Elife Año: 2022 Tipo del documento: Article País de afiliación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Melanoma Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: Elife Año: 2022 Tipo del documento: Article País de afiliación: Francia